Loading clinical trials...
Loading clinical trials...
Effects of Nebivolol on Left Ventricular and Left Atrial Morphodynamics in Adults With Hypertension and Isolated Diastolic Dysfunction
To investigate whether treatment with Nebivolol in subjects with high blood pressure and abnormal filling of left ventricle (LVDD) improves exercise time by improving Left Ventricular deformation and filling.
Background: The left ventricle (LV) ejects blood with a wringing motion, where the LV apex rotates counterclockwise and the base rotates in clockwise directions respectively. Rapid untwisting and recoil of LV during isovolumic relaxation and early diastole releases energy stored in ejection for LV suction and rapid early diastolic restoration. The LV geometry and its rotational mechanics also give rise to intracavitary blood flow rotation resulting into LV intracavitary vortex ring formation. LV torsion and vortex ring formation confer morphodynamic advantages that gain importance as blood flow velocities, heart rate and rates of change of momentum increase with exertion for improving LV efficiency. We have recently characterized the significance of LV twist mechanics and vortex ring formation in human hearts using novel high resolution speckle and contrast particle tracking echocardiography. Although data on a favorable effect of nebivolol on exercise capacity and LV diastolic filling exists, the changes in left ventricular (LV) rotational mechanics and blood flow vortex ring formation that may explain the potential hemodynamic benefits seen with nebivolol have not been previously characterized. Aims: In patients with hypertension and left ventricular diastolic dysfunction (LVDD) treatment with nebivolol for 6 months improves exercise time by enhancing: 1. LV deformation, torsion and untwisting mechanics 2. LA-to-LV blood flow transport and characteristics of intra-cavitary vortex formation 3. LA reservoir and booster pump function and LA-LV interaction during the conduit phase Hypotheses: Treatment with nebivolol in subjects with hypertension and LVDD improves exercise time by improving LV deformation and diastolic filling. As diastole shortens with the tachycardia associated with exercise, the contribution of untwist becomes relatively more important to LV suction and filling. Nebivolol improves LV diastolic filling primarily by enhancing LV untwisting and the rheological efficiency of blood flow transport through vortex formation in early diastole. Significance: Patients with LVDD are asymptomatic at rest and often but become markedly symptomatic with exertion. This pilot study will provide data for the first time for correlating the improvement in exercise capacity seen with the use of nebivolol with the changes in LV relaxation, torsional mechanics, LV vortex formation and LA-LV transport functions. The preliminary data will be essential for understanding the underlying pathophysiological mechanisms through which nebivolol improves exercise hemodynamics besides providing data for development of subsequent larger randomized multicentric trials.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Start Date
March 1, 2012
Primary Completion Date
March 1, 2016
Completion Date
March 1, 2016
Last Updated
November 24, 2017
70
ACTUAL participants
Nebivolol
DRUG
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
NCT02417740
NCT07073820
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07480265